综述 Review

非小细胞肺癌中RET融合基因的研究进展

Published at: 2015年第35卷第2期

方霆 1 , 李代强 1
1 中南大学湘雅二医院病理科,长沙 410011
通讯作者 代强 李 Email: lidqxf@163.com
DOI: 10.3978/j.issn.2095-6959.10.3978/j.issn.2095-6959.2015.02.026
基金:

摘要

存在于1%~2%的非小细胞肺癌患者中的RET融合基因具有鲜明的临床病理学特征,且RET抑制剂 对其治疗有效,提示RET融合基因已成为该类患者个体化分子靶向治疗的新靶点。本文将对RET 融合基因的特点及其在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中的表达和治疗的研 究进展进行阐述。


Research progress of RET fusion gene in non-small cell lung cancer

Abstract

RET fusion gene with an identifiable clinicopathological characteristics, is present in 1% to 2% of non-small cell lung cancer patients, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene is a new target for individualized treatment to the patients of NSCLC. This article reviews the characteristics of RET fusion gene and expression patterns in patients, and treatment of NSCLC.


comments powered by Disqus

全文

引用

引用本文: 霆 方, 代强 李. 非小细胞肺癌中RET融合基因的研究进展[J]. 临床与病理杂志, 2015, 35(2): 284-288.
Cite this article as: FANG Ting, LI Daiqiang . Research progress of RET fusion gene in non-small cell lung cancer[J]. Journal of Clinical and Pathological Research, 2015, 35(2): 284-288.